非男性因素不孕患者中卵胞浆内单精子注射与常规体外受精的比较
该回顾性队列研究纳入2014年1月至2015年12月首次自体取卵的非男性因素不孕患者46,967例,比较卵胞浆内单精子注射(ICSI)与常规体外受精(cIVF)的累积活产率(CLBR)及成本效益。无胚胎植入前非整倍体遗传学检测(PGT-A)周期中,ICSI组CLBR为60.9%,cIVF组为64.3%,校正后无显著差异(校正风险比0.99,95%CI 0.99-1.00)。作者认为ICSI未改善CLBR,且增加额外费用,常规使用ICSI不必要。
要点
- 非男性因素不孕患者中,ICSI组CLBR为60.9%,cIVF组为64.3%,校正后无显著差异(校正风险比0.99,95%CI 0.99-1.00)。
- PGT-A周期中,ICSI组与cIVF组CLBR分别为64.7%与69.0%,校正后无差异(校正风险比0.97,95%CI 0.93-1.01)。
- 作者认为,鉴于额外费用且无CLBR获益,非男性因素不孕患者常规使用ICSI不必要。
核心结论
- 在非男性因素不孕患者中,ICSI未改善累积活产率。
- 鉴于额外费用且无CLBR获益,作者认为非男性因素不孕患者常规使用ICSI不必要。
研究设计与样本
- 回顾性队列研究,纳入美国辅助生殖技术协会(SART)诊所2014年1月至2015年12月首次自体取卵的非男性因素不孕患者46,967例。
- 主要结局为CLBR,定义为2014至2015年自体取卵周期中最多1次活产,并链接至2016年的新鲜与冷冻胚胎移植。
- 分析在有无PGT-A的亚样本中分别进行,并进行成本分析以确定ICSI产生的费用。
主要发现
- 无PGT-A周期中,ICSI组CLBR为60.9%,cIVF组为64.3%,校正协变量后差异无统计学显著(校正风险比0.99,95%CI 0.99-1.00)。
- 有PGT-A周期中,ICSI组与cIVF组CLBR分别为64.7%与69.0%,校正后无差异(校正风险比0.97,95%CI 0.93-1.01)。
- SART诊所在2年内对无基因检测的ICSI额外收费估计为37,476,000美元,对联合PGT-A的ICSI额外收费估计为7,213,500美元。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the cumulative live birth rates (CLBRs) and cost effectiveness of intracytoplasmic sperm injection (ICSI) and conventional in vitro fertilization (cIVF) for non-male factor infertility. DESIGN: A retrospective cohort study. SETTING: Society for Assisted Reproductive Technology clinics. PATIENT(S): A total of 46,967 patients with non-male factor infertility with the first autologous oocyte retrieval cycle between January 2014 and December 2015. INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): The primary outcomes were CLBR, defined as up to 1 live birth from an autologous retrieval cycle between 2014 and 2015, and linked fresh and frozen embryo transfers through 2016. The secondary outcomes included miscarriage rate, 2 pronuclei per oocyte retrieved, and the total number of transferred and frozen embryos. Analyses were performed on subsamples with and without preimplantation genetic testing for aneuploidy (PGT-A). A cost analysis was performed to determine the costs accrued by ICSI. RESULT(S): Among cycles without PGT-A in patients with non-male factor infertility, the CLBR was 60.9% for ICSI cycles vs. 64.3% for cIVF cycles, a difference that was not significantly different after adjustment for covariates (adjusted risk ratio, 0.99; 95% confidence interval, 0.99-1.00). With PGT-A, no difference in CLBR was found between ICSI and cIVF cases after adjustment (64.7% vs. 69.0%, respectively; adjusted risk ratio, 0.97; 95% confidence interval, 0.93-1.01). The patients were charged an estimated additional amount of $37,476,000 for ICSI without genetic testing and an additional amount of $7,213,500 for ICSI with PGT-A over 2 years by Society for Assisted Reproductive Technology clinics. CONCLUSION(S): In patients with non-male factor infertility, ICSI did not improve CLBR. Given the additional cost and the lack of CLBR benefit, our data show that the routine use of ICSI in patients with non-male factor infertility is not warranted.
引用
- Iwamoto A, Van Voorhis BJ, Summers KM, et al. Intracytoplasmic sperm injection vs. conventional in vitro fertilization in patients with non-male factor infertility. Fertil Steril. 2022. PMID: 35835597. doi:10.1016/j.fertnstert.2022.06.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。